Disease relevance of oxaprozin

• The smaller volume of distribution is consistent with a decrease in oxaprozin tissue binding in azotemia [1].
• Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics [2].
• Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee [3].
• One subject who received oxaprozin for 12 days and, in addition, aspirin for the last five days developed a rash that subsided after both drugs were discontinued; one subject treated with aspirin experienced tinnitus [4].
• A case of Stevens-Johnson syndrome associated with oxaprozin therapy [5].

Psychiatry related information on oxaprozin

• At week 6, oxaprozin treatment resulted in significantly greater improvement than placebo in physical functioning, role physical, and bodily pain (P < 0.05); social functioning, role emotional, and mental health (P < 0.01); and vitality and MCS score (P < 0.001) [6].

High impact information on oxaprozin

• Panic disorder in a patient taking oxaprozin [7].
• The effects of renal disease on the steady-state kinetics of oxaprozin were assessed in eight patients on hemodialysis with normal serum albumin levels and eight normal subjects who received six doses [2].
• The mean total AUC, peak concentration, average steady-state plasma concentration, and trough concentration for total and unbound oxaprozin were decreased in the patients on hemodialysis [2].
• The frequency of probably drug-related AST elevations was highest (5%) with aspirin; with oxaprozin, an investigational nonsteroidal antiinflammatory drug, the incidence (3%) fell between that for the other two agents [8].
• The decreased plasma and tissue binding and lower Clint suggest that, in the treatment of azotemic patients with rheumatoid arthritis, the dose of oxaprozin should begin at 600 mg once a day [1].

Chemical compound and disease context of oxaprozin

• This multicenter, 6-week, double-blind, placebo-controlled, parallel-group study compared the efficacy and safety of oxaprozin 1200 mg once daily with that of nabumetone 1000 mg once daily in patients with moderate-to-severe osteoarthritis (OA) of the knee [3].
• CONCLUSIONS: As expected, once-daily oxaprozin proved to be as effective as diclofenac three times daily in reducing the primary efficacy variable of patient-assessed shoulder pain score in patients with periarthritis of the shoulder refractory to previous treatments with other NSAIDs [9].
• A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis [10].

Biological context of oxaprozin

• Metabolism and kinetics of oxaprozin in normal subjects [11].
• Oxaprozin is eliminated following biotransformation to glucuroconjugated metabolites which are excreted in urine and bile, with little drug being eliminated unchanged [12].
• A significant drug interaction has been demonstrated between oxaprozin and aspirin (acetylsalicylic acid) [12].
• The data from the protein binding study showed that oxaprozin was more than 99 per cent bound to plasma proteins [4].
• The results of this study indicate that the ingestion of food has no effect on the bioavailability of oxaprozin [13].

Anatomical context of oxaprozin

• Substantial concentrations of oxaprozin are attained in synovial fluid, which is a proposed site of action for nonsteroidal anti-inflammatory drugs [12].
• Studies were performed in rats and mice to investigate the mechanisms of the comparatively low irritancy in the gastrointestinal (GI) tract of oxaprozin, relative to that of other non-steroidal anti-inflammatory drugs [14].
• A single dose of oxaprozin (100 mg/kg), given orally to rats, reduced the concentration of prostaglandin E2, but did not produce any gastric lesions or mucosal irritation, either visibly or when the mucosa was examined by scanning or transmission electronmicroscopy [14].
• Gastroscopic evaluation of the effect of aspirin and oxaprozin on the gastric mucosa [15].
• To evaluate the influence of indomethacin and oxaprozin on reproductive function in healthy young men, 34 volunteers with normal semen parameters were recruited [16].

Associations of oxaprozin with other chemical compounds

• The risk of GI-event-related hospitalizations was greatest among women exposed to diflunisal (RR = 6.08; 95% CI = 2.27-16.26) or oxaprozin (RR = 6.03; 95% CI = 2.49-14.58) [17].
• In addition, oxaprozin showed a trend toward superior results in improving patients' quality of life compared with diclofenac [9].
• (1976), also called the benzodiazepine binding site (Müller and Wollert 1975), inhibit these reactions with oxaprozin glucuronide, while ligands which are known to bind at other sites on HSA do not [18].
• Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib [19].
• Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives [20].

Gene context of oxaprozin

• Studies have also shown oxaprozin to be effective therapy for juvenile rheumatoid arthritis and ankylosing spondylitis [21].
• At week 2, the oxaprozin group showed significantly greater improvement than the placebo group in role physical, vitality, and mental component summary (MCS) scores (P < 0.05), and in physical functioning, bodily pain, social functioning, and physical component summary (PCS) scores (P < 0.01) [6].
• Hydrolysis and rearrangement (isomerization by acyl migration) of oxaprozin glucuronide are greatly accelerated by plasma and human serum albumin [22].

Analytical, diagnostic and therapeutic context of oxaprozin

• These differences are consistent with impaired absorption of oxaprozin in patients on hemodialysis [2].
• Oxaprozin is a nonsteroidal anti-inflammatory drug which reaches peak plasma concentrations 2 to 6 hours after oral administration [12].
• Twelve normal subjects each received single 300-, 600-, and 1200-mg oral doses of oxaprozin according to a three-period crossover design [23].
• Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine [24].
• The binding of the non-steroidal anti-inflammatory drug oxaprozin to human serum albumin was studied by bioaffinity high-performance liquid chromatography using a column based on immobilized human serum albumin [25].

References